Tapentadol is partly metabolized with the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with prescription drugs that enrich or repress the activity/expression of a number of of these enzymes, together with with substrates of these enzymes (resulting from Opposition for the enzyme); some enzyme mediators/substrates call